Maternal Serum Stathmin-1 Levels in Preeclampsia

This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pre-eclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pregnancy Complications Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Cam and Sakura City Hospital

Istanbul, 34480, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Preeclampsia: Defined by New-onset hypertension (Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg) after 20 weeks of gestation, with or without proteinuria.
Clinical diagnosis of Severe Preeclampsia: Defined by criteria such as severe hypertension (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction.
Control Group: Healthy pregnancies without preeclampsia

Exclusion criteria

Multiple Pregnancies
Pregestational Diabetes
Chronic Hypertension
Systemic Diseases (Chronic kidney disease, autoimmune diseases)
Fetal Anomalies
Premature Rupture of Membranes

Treatment and study plan

Primary outcomes

Maternal Serum Stathmin-1

Time frame: Up to 8 weeks (Patients will be followed from inclusion in the study until the end of their pregnancy.)

To compare Stathmin-1 Levels between the pre-eclampsia and the control group.

Sponsors and collaborators

Lead sponsor

Başakşehir Çam & Sakura City Hospital

Other Gov

Registry information

Official study title

A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia, Severe Preeclampsia, and Healthy Controls

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Oct 2, 2024
Registry last updated: Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed